Twist Bioscience Corporation
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthes...
Latest News
1 month ago · benzinga.com
Twist Bioscience Stock Hits New High, Then Retreats: What's Happening?Twist Bioscience Corp. (NASDAQ:TWST) shares are trading lower Friday, pulling back after touching a fresh 52-week high near $192 earlier in the session. Here's what you should know.
1 month ago · fool.com
Why Twist Bioscience Stock Skyrocketed This WeekThe biotech will both contribute to and draw from its findings. It'll also earn revenue from its participation.
2 months ago · benzinga.com
Beyond Hype: Twist Bioscience Secures Data Pipeline Role In Eli Lilly TuneLab EcosystemTwist Bioscience Corporation (NASDAQ:TWST) on Wednesday announced an agreement with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Co. (NYSE:LLY).
2 months ago · gurufocus.com
Twist Bioscience Joins Lilly TuneLab to Advance Antibody Drug Discovery[url="]Twist Bioscience Corporation[/url] (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced an agreement with Lilly TuneLab, a collabo
2 months ago · seekingalpha.com
Twist Biosciences: AI-Driven Rally Or Short Squeeze? I'm Neutral (For Now)Twist Bioscience Corporation is rated Hold, as its $9.5bn valuation appears disconnected from current fundamentals, and profitability remains elusive. TWST's recent 200% stock surge is driven by AI-related news, short squeeze dynamics, and strong DSPS revenue growth, not by blowout earnings. Full-year 2026 guidance was raised to $456–$457m revenue with adjusted EBITDA breakeven targeted, but losses and elevated SG&A persist.
3 months ago · benzinga.com
Twist Bioscience Stock Resilient Despite Scorpion Capital Short ReportTwist Bioscience Corp (NASDAQ:TWST) shares surged Wednesday after Anthropic named the company an independent evaluator in a new AI-driven protein design campaign.
3 months ago · seekingalpha.com
Twist Biosciences: Accelerating Growth, Diminishing Margin Of SafetyTwist Bioscience's stock has surged in 2026 on the back of improved growth and growing optimism about the AI-enabled drug discovery opportunity. Growth will be driven by triple-digit AI-enabled drug discovery order growth, and oncology diagnostic assay commercialization. Operating leverage, manufacturing improvements, and the introduction of higher value-add products will also see Twist's margins continue to improve.
3 months ago · gurufocus.com
Twist Bioscience Announces Pricing of Upsized $300.0 Million Public Offering of Common StockTwist Bioscience Corporation (Nasdaq: TWST) (âTwistâ), a mid-cap growth and value biotech company, today announced the pricing of an upsized underwritten pu
3 months ago · businesswire.com
Twist Bioscience Announces Proposed Public Offering of $250.0 Million of Common StockSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (Nasdaq: TWST) (“Twist”), a mid-cap growth and value biotech company, today announced the commencement of an underwritten public offering of $250.0 million of shares of its common stock. In addition, Twist intends to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of its common stock. All of the shares of common stock to be sold in the proposed offering are being offered by.
3 months ago · seekingalpha.com
Twist Bioscience Corporation (TWST) Q3 2026 Earnings Call TranscriptTwist Bioscience Corporation (TWST) Q3 2026 Earnings Call Transcript
Analyst Summary
Add to Watchlist
Select watchlists to add or remove TWST